close
close
Tesla, Alibaba, Eli Lilly, Novo Nordisk and Glencore

Tesla, Alibaba, Eli Lilly, Novo Nordisk and Glencore

by

The shares of the electric vehicle manufacturer Tesla (TSLA) have decreased to their highest point since February, since the investor optimism is trade negotiations in the USA.

Scott Bessent, Finance Minister of the US Financing, said on Monday morning that the United States and China had agreed to reduce its tariffs for imports of 115% for 90 days, after negotiations in Switzerland at the weekend.

Read more: Gold makes a dive as a US China trade agreement that deals with the Safe-Haven appointment authority

In a briefing in Geneva on Monday, Bessent reporters said that “both sides showed great respect in their trade talks and that they” both have an interest in balanced trade “.

Optimism about the latest developments has contributed to increasing the Tesla shares higher, with the shares increased by 9.6% last month. The share was also increased when CEO Elon Musk said after the company's income was released that he would spend more time at Tesla and less time in Washington in his role in President Donald Trump's Department of Government Efficiency (Doge).

The shares of the Chinese Tech-Riese Alibaba (9988.hk, Baba) rose by 2.5%on Monday, which was optimistic in the markets in the areas of US China trade talks.

Alibaba will report its results of the entire year on Thursday, whereby investors keep an eye on both the performance in e-commerce and developments in artificial intelligence (AI).

Deren Nathan, head of the stock analysis at Hargreaves Lansdown, said that analysts had predicted sales growth of 6.2% compared to the previous year for 2025.

Read more: FTSE 100 LIVE: Shares rise higher because the USA and China temporarily agree to reduce tariffs

He said that Alibaba “made remarkable progress in the past quarter the expansion of his aspiring KI and Cloud infrastructure department, which became of central importance for its growth strategy”.

“While the focus on AI and Cloud makes the headlines, most of the income still comes from e-commerce, which makes Chinese consumers decisive,” said Nathan.

“The persistent macroeconomic uncertainties in China will remain important factors that influence investors' trust in the coming year. The main question is now whether the dynamics can be maintained in the next quarter and next year.”

The US Pharmaceuticals-Riese Eli Lilly (Lly) said on Sunday that his medication Zepbound “superior weight loss” showed Wegovy to Novo Nordisks (Novo-B.Co).

Carding the results of a clinical study, Eli Lilly said that the participants treated with Zepbound achieved an average weight reduction of 20.2% compared to 13.7%, with Wegovy after 72 weeks.

Leave a Comment